Optimal control algorithm for continuous processes with switching operations

具有切换操作的连续过程的最优控制算法

• 批准号: 570868-2021
• 负责人: Liu, Jinfeng
• 金额: $ 2.19万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=722774
• 关键词: Optimal; control; algorithm; continuous; processes

Drugs based on mAbs play an indispensable role in biopharmaceutical industry in aspects of therapeutic and market potentials. According to a recent publication, mAbs also show promising results in the treatment of COVID-19. Increasing the production capacity of mAb manufacturing processes is immediately necessary due to the explosive growth in mAb market. Replacing the current batch processes by continuous manufacturing processes is recognized as the solution to address the explosive market needs. As we move towards continuous manufacturing in (bio)pharmaceutical, processes with frequent switching operations become more and more common. When to perform the switching between the subprocesses is critical in ensuring product quality and process profitability. The continuous manufacturing of mAb is a representative such process and has attracted much research attention. The proposed project focuses on the optimal control aspect of continuous mAb manufacturing and addresses a particular issue in mAb manufacturing, which has received little attention. Canada is an active and competitive contributor to the development of high capacity mAb manufacturing processes. This project will (a) further enhance the competitiveness of Canada in biopharmaceutical industry, (b) train highly qualified personnel (HQP) that have interdisciplinary backgrounds in biopharmaceutical and control engineering, and (c) create more job opportunities in Quartic.ai in the near future.

基于单克隆抗体的药物在治疗和市场潜力方面在生物制药工业中发挥着不可或缺的作用。根据最近的出版物，mAb在COVID-19的治疗中也显示出有希望的结果。由于mAb市场的爆炸性增长，提高mAb生产工艺的生产能力是当务之急。用连续生产工艺取代当前的批处理工艺被认为是解决爆炸性市场需求的解决方案。随着我们在（生物）制药领域朝着连续生产的方向发展，频繁切换操作的工艺变得越来越普遍。何时在子流程之间进行切换对于确保产品质量和流程盈利能力至关重要。单克隆抗体的连续生产是一种典型的生产工艺，并引起了广泛的研究关注。拟议的项目侧重于连续mAb生产的最佳控制方面，并解决了mAb生产中的一个特殊问题，这一问题很少受到关注。加拿大是开发高产能mAb生产工艺的积极和有竞争力的贡献者。该项目将（a）进一步提高加拿大在生物制药行业的竞争力，（B）培养具有生物制药和控制工程跨学科背景的高素质人才（HQP），（c）在不久的将来创造更多的就业机会。Quartic.ai